Chimeric antigen receptor (CAR) T‐cell therapy redirected to specific antigens on tumor cells is a promising treatment strategy for relapsed/refractory tumors, which cannot be cured by current standard treatments.1, 2 CAR T‐cell therapy specific to the CD19 molecule has achieved considerable success in a subset of patients with highly refractory B‐cell tumors,3, 4, 5, 6 and various CAR T‐cell products are being extended to treat other cancers including myeloid malignancies7 and solid tumors.8 Here, CD19 is linked to neoplasm.